ナルトレキソンとブプレノルフィンの世界市場規模、シェア、動向分析：製品別、投与経路別、用途別、流通チャネル別、地域別、セグメント別予測（2024年～2030年）

ナルトレキソンとブプレノルフィン市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のナルトレキソンとブプレノルフィンの市場規模は、2030年までに84億2,000万米ドルに達し、2024年～2030年のCAGRは12.41%で成長すると予測されています。

同市場が成長を遂げている主な要因は、薬物使用障害の発生率の上昇、危機的状況に対処するための政府の取り組みの増加、オピオイド使用障害の治療に対する意識の高まりです。これらの要因は、予測期間中に業界の拡大を大幅に後押しし、依存症ケアソリューションの進歩とアクセシビリティの向上を促進すると予測されます。

World Drug Report 2023は、薬物使用障害の世界の動向に焦点を当て、オピオイドが過剰摂取による死亡の主な原因であり、障害や早死による損失年数の大きな要因であることを強調しています。オピオイド使用障害（OUD）は世界中で数百万人が罹患しており、COVID-19の大流行によって治療アクセスの格差が悪化しています。主な乱用薬物には、欧州とアジアではオピオイド、ラテンアメリカではコカイン、東アジアと東南アジアではメタンフェタミンなど、地域差があります。スティグマと差別が治療努力を妨げており、支援を必要としている人のうち、治療を受けている人は20％にも満たない状況です。報告書は、こうした複雑な健康問題や社会的課題に取り組むための国際協力を求めています。

さらに、多面的なアプローチを通じてOUDの危機と闘う政府の取り組みが増加しています。2024年2月、SAMHSAの承認により、地域精神保健サービス・ブロック補助金および薬物使用予防・治療・回復サービス・ブロック補助金の補助金4,660万米ドルが、精神保健および薬物使用サービスに割り当てられました。さらに、米国財務省の資金6,750万米ドルが、ウィスコンシン州のこうした取り組みを支援するために充てられました。

さらに、業界各社は、流通網の強化、医療提供者との戦略的提携、研究開発投資の拡大などの戦略的イニシアティブを通じて、市場の成長を推進しています。例えば、2023年7月、Titan Pharmaceuticals, Inc.とFedson, Inc.は資産売買契約を締結し、TitanはProNeuraの資産の一部を売却することになりました。この契約では、薬物依存症治療薬のポートフォリオや、ProNeuraドラッグデリバリー技術に基づいて構築されたその他の初期開発イニシアチブなどが含まれます。同社の薬物依存症ポートフォリオは、ナルメフェンとプロブフィンのインプラントプログラムで構成されていました。さらに2023年9月、Camurus ABは、中等度から重度のOUD治療を適応とするブリクサディを含む週1回および月1回の投薬であるブリクサディを発表しました。これらの取り組みは、治療へのアクセスや有効性を拡大し、進歩を大きく推進することを目的としています。

ナルトレキソンとブプレノルフィン市場レポートハイライト

• 強固なヘルスケアインフラ、薬物使用障害の高い有病率、依存症治療を支援する政府の積極的な取り組みが原動力となり、2023年には北米が39.39%の最大売上シェアを占めました。
• 製品別では、ブプレノルフィンセグメントが2023年に70.02%のシェアで市場を独占し、予測期間中にCAGRで最速の成長が見込まれます。同分野の成長は、製品の上市、提携、M&A、規制当局の承認、有効性を証明する臨床試験、治療開始率を高めるその他の要因など、主要企業が採用した様々な戦略に起因すると考えられます。
• 投与経路別では、経口投与セグメントは2023年に55.87％の大半のシェアを占めました。しかし、ブプレノルフィンセグメントでは、注射剤投与が2023年に65.04%の大半のシェアを占めました。
• 用途別では、OUDセグメントが2023年に69.03%のシェアを占めました。ナルトレキソンは、OUDの管理に有効であることが広く認められており、治療プログラムでの広範な採用につながっています。
• 流通チャネル別では、院内薬局が2023年に48.26%のシェアを占め、世界市場を席巻しました。院内薬局の成長は、ブプレノルフィンなどの非経口OUD治療薬の投与、医師の監視下での治療の確保、必要不可欠な医薬品へのアクセスの促進において重要な役割を果たすことに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ナルトレキソンとブプレノルフィン市場の変数、動向、範囲

• ナルトレキソンとブプレノルフィンの市場系統の展望
  • 親市場の見通し
  • 補助市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ナルトレキソンとブプレノルフィンの市場分析ツール
  • ポーターのファイブフォース分析
  • PESTLE分析
• パイプライン分析
• 価格分析
• インプラント治療を選択する際の患者と医療提供者の考慮事項
• 対象人口分析
• ナルトレキソンとブプレノルフィン皮下吸収性インプラントの総アドレス可能市場（TAM）分析

第4章 ナルトレキソンとブプレノルフィンの市場分析：製品別（2018年～2030年）

• ナルトレキソンとブプレノルフィン：製品の変動分析
• ナルトレキソンとブプレノルフィンの市場分析：製品市場別
• ナルトレキソン
  • 市場収益推計と予測（2018年～2030年）
• ブプレノルフィン
  • 市場収益推計と予測（2018年～2030年）
  • ベルブカ
  • サブロケード
  • サブオキソン
  • ズブソルフ
  • その他

第5章 ナルトレキソンとブプレノルフィンの市場分析：投与経路別（2018年～2030年）

• ナルトレキソンとブプレノルフィン：投与経路の変動分析
• ナルトレキソンとブプレノルフィンの市場分析：投与経路市場別
• ナルトレキソン
  • 市場収益推計と予測（2018年～2030年）
  • 経口投与
  • 注射剤投与
  • 埋め込み型投与
• ブプレノルフィン
  • 市場収益推計と予測（2018年～2030年）
  • 経口投与
  • 注射剤投与
  • 埋め込み型投与

第6章 ナルトレキソンとブプレノルフィンの市場分析：用途別（2018年～2030年）

• ナルトレキソンとブプレノルフィン：用途の変動分析
• ナルトレキソンとブプレノルフィンの市場分析：用途市場別
• ナルトレキソン
  • 市場収益推計と予測（2018年～2030年）
  • オピオイド使用障害（OUD）
• ブプレノルフィン
  • 市場収益推計と予測（2018年～2030年）
  • オピオイド使用障害（OUD）

第7章 ナルトレキソンとブプレノルフィンの市場分析：流通チャネル別（2018年～2030年）

• ナルトレキソンとブプレノルフィン：流通チャネルの変動分析
• ナルトレキソンとブプレノルフィンの市場分析：流通チャネル市場別
• 院内薬局
  • 市場収益推計と予測（2018年～2030年）
• 小売薬局
  • 市場収益推計と予測（2018年～2030年）
• その他
  • 市場収益推計と予測（2018年～2030年）

第8章 ナルトレキソンとブプレノルフィン市場：製品別、投与経路別、用途別、流通チャネル別の地域推定・動向分析

• ナルトレキソンとブプレノルフィン市場：地域別展望
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第9章 競合情勢

• 市場参入企業の分類
• 主要企業プロファイル
  • Indivior PLC
  • Collegium Pharmaceutical, Inc.（BioDelivery Sciences International, Inc.の親会社）
  • Alkermes plc
  • Orexo AB
  • Titan Pharmaceuticals, Inc.
  • Omeros Corporation
  • F. Hoffmann-La Roche Ltd.
  • Camurus
  • Sun Pharmaceutical Industries Ltd
  • Braeburn, Inc.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 4 Global naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 5 Global naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 6 Global naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7 North America naltrexone and buprenorphine market, by region, 2018 - 2030 (USD Million)
• Table 8 North America naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 9 North America naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 10 North America naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 11 North America naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 12 U.S. naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 13 U.S. naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 14 U.S. naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 15 U.S. naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 16 Canada naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 17 Canada naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 18 Canada naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 19 Canada naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20 Mexico naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 21 Mexico naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 22 Mexico naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 23 Mexico naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 Europe naltrexone and buprenorphine market, by country, 2018 - 2030 (USD Million)
• Table 25 Europe naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 26 Europe naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 27 Europe naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 28 Europe naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 29 UK naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 30 UK naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 31 UK naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 32 UK naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 33 Germany naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 34 Germany naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 35 Germany naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 36 Germany naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 37 France naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 38 France naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 39 France naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 40 France naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 41 Italy naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 42 Italy naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 43 Italy naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 44 Italy naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 45 Spain naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 46 Spain naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 47 Spain naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 48 Spain naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 49 Norway naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 50 Norway naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 51 Norway naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 52 Norway naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 53 Sweden naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 54 Sweden naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 55 Sweden naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 56 Sweden naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 57 Denmark naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 58 Denmark naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 59 Denmark naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 60 Denmark naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific naltrexone and buprenorphine market, by country, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 66 Japan naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 67 Japan naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 68 Japan naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 69 Japan naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 70 China naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 71 China naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 72 China naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 73 China naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 74 India naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 75 India naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 76 India naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 77 India naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 78 Australia naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 79 Australia naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 80 Australia naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 81 Australia naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 82 South Korea naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 83 South Korea naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 84 South Korea naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 85 South Korea naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 86 Thailand naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 87 Thailand naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 88 Thailand naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 89 Thailand naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90 Latin America naltrexone and buprenorphine market, by country, 2018 - 2030 (USD Million)
• Table 91 Latin America naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 92 Latin America naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 93 Latin America naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 94 Latin America naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 95 Brazil naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 96 Brazil naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 97 Brazil naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 98 Brazil naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 99 Argentina naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 100 Argentina naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 101 Argentina naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 102 Argentina naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 103 Middle East & Africa naltrexone and buprenorphine market, by country, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 108 South Africa naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 109 South Africa naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 110 South Africa naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 111 South Africa naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 116 UAE naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 117 UAE naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 118 UAE naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 119 UAE naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)
• Table 120 Kuwait naltrexone and buprenorphine market, by product, 2018 - 2030 (USD Million)
• Table 121 Kuwait naltrexone and buprenorphine market, by route of administration, 2018 - 2030 (USD Million)
• Table 122 Kuwait naltrexone and buprenorphine market, by application, 2018 - 2030 (USD Million)
• Table 123 Kuwait naltrexone and buprenorphine market, by distribution channel, 2018 - 2030 (USD Million)

List of Fig.ures

Fig. 1 Naltrexone and buprenorphine market segmentation

Fig. 2 Market research process

Fig. 3 Data triangulation techniques

Fig. 4 Primary research pattern

Fig. 5 Market research approaches

Fig. 6 Value chain-based sizing & forecasting

Fig. 7 QFD modelling for market share assessment

Fig. 8 Market formulation & validation

Fig. 9 Market snapshot

Fig. 10 Molecule and sales channel segment snapshot

Fig. 11 Competitive landscape snapshot

Fig. 12 Global Pharmaceutical Market, (USD billion)

Fig. 13 Market dynamics

Fig. 14 Porter's five forces analysis

Fig. 15 PESTLE analysis

Fig. 16 Naltrexone and buprenorphine: Product outlook and key takeaways

Fig. 17 Naltrexone and buprenorphine market: Product market movement analysis

Fig. 18 Naltrexone market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 19 Buprenorphine market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 20 BELBUCA market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 21 Sublocade market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 22 Suboxone market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 23 Zubsolv market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 25 Naltrexone and buprenorphine: Route of administration outlook and key takeaways

Fig. 26 Naltrexone and buprenorphine market: Route of administration market movement analysis

Fig. 27 Naltrexone market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 28 Oral administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 29 Injectable administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 30 Implantable administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 31 Buprenorphine market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 32 Oral administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 33 Injectable administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 34 Implantable administration market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 35 Naltrexone and buprenorphine: Application outlook and key takeaways

Fig. 36 Naltrexone and buprenorphine market: Application market movement analysis

Fig. 37 Naltrexone market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 38 Opioid Use Disorder (OUD) market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 39 Alcohol use disorder (AUD) market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 40 Buprenorphine market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 41 Opioid Use Disorder (OUD) market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 42 Naltrexone and buprenorphine: Distribution channel outlook and key takeaways

Fig. 43 Naltrexone and buprenorphine market: Distribution channel market movement analysis

Fig. 44 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 45 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 46 Other market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 47 Naltrexone and buprenorphine market revenue, by region, 2023 & 2030, USD Million

Fig. 48 Regional marketplace: Key takeaways

Fig. 49 Regional marketplace: Key takeaways

Fig. 50 North America naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 51 Key country dynamics

Fig. 52 U.S. naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 53 Key country dynamics

Fig. 54 Canada naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 55 Key country dynamics

Fig. 56 Mexico naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 57 Regulatory framework

Fig. 58 Europe naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 59 Key country dynamics

Fig. 60 UK naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 61 Key country dynamics

Fig. 62 Germany naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 63 Key country dynamics

Fig. 64 France naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 65 Key country dynamics

Fig. 66 Spain naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 67 Key country dynamics

Fig. 68 Italy naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 69 Key country dynamics

Fig. 70 Denmark naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 71 Key country dynamics

Fig. 72 Sweden naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 73 Key country dynamics

Fig. 74 Norway naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 75 Rest of Europe naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 76 Asia Pacific naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 77 Key country dynamics

Fig. 78 Japan naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 79 Key country dynamics

Fig. 80 China naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 81 China regulatory details

Fig. 82 India naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 83 Key country dynamics

Fig. 84 Australia naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 85 Key country dynamics

Fig. 86 Thailand naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 87 Key country dynamics

Fig. 88 South Korea naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 89 Rest of Asia Pacific naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 90 Latin America naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 91 Key country dynamics

Fig. 92 Brazil naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 93 Brazil regulation details

Fig. 94 Key country dynamics

Fig. 95 Argentina naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 96 Argentina regulatory framework

Fig. 97 Rest of Latin America naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 98 Key country dynamics

Fig. 99 South Africa naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 100 Key country dynamics

Fig. 101 Saudi Arabia naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 102 Key country dynamics

Fig. 103 UAE naltrexone and buprenorphine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 104 Key country dynamics

Fig. 105 Kuwait naltrexone and buprenorphine market estimates and forecasts, 2018

Fig. 106 Rest of MEA naltrexone and buprenorphine market estimates and forecasts,

Fig. 107 Company/competition categorization

Fig. 108 Company market share analysis, 2023

Fig. 109 Strategy mapping

Naltrexone And Buprenorphine Market Growth & Trends:

The global naltrexone and buprenorphine market size is expected to reach USD 8.42 billion by 2030, growing at a CAGR of 12.41% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing growth primarily due to the rising incidence of substance use disorders, increasing government efforts to address the crisis, and growing awareness of treatments for opioid use disorder. These factors are anticipated to substantially boost industry expansion during the forecast period, fostering advancements and improving accessibility to addiction care solutions.

The World Drug Report 2023 highlights global trends in drug use disorders, emphasizing opioids as the primary cause of death from overdose and significant contributors to years lost due to disability and premature death. Opioid Use Disorder (OUD) affects millions worldwide, with disparities in treatment access exacerbated by the COVID-19 pandemic. Regional variations in primary drugs of abuse include opioids in Europe and Asia, cocaine in Latin America, and methamphetamine in East & Southeast Asia. Stigma and discrimination hinder treatment efforts, with less than 20% of those needing help receiving it. The report calls for international cooperation to address these complex health and societal challenges.

Furthermore, increasing government initiatives to combat the OUD crisis through multifaceted approaches are growing. In February 2024, with the approval of the SAMHSA, USD 46.6 million in supplemental Community Mental Health Services Block Grant and Substance Use Prevention, Treatment, and Recovery Services Block Grant funds have been allocated to mental health and substance use services. In addition, USD 67.5 million from U.S. Department of Treasury funds has been directed to support these efforts in Wisconsin.

Moreover, industry players are driving growth in the market through strategic initiatives, such as enhanced distribution networks, strategic partnerships with healthcare providers, and increased research and development investments. For instance, in July 2023, Titan Pharmaceuticals, Inc. and Fedson, Inc. signed an Asset Purchase Agreement, under which Titan would sell part of ProNeura assets, such as its portfolio of medications for drug addiction and other early development initiatives built on the ProNeura drug delivery technology. The company's addiction portfolio comprised implant programs for Nalmefene and Probuphine. In addition, in September 2023, Camurus AB introduced Brixadi, a weekly and monthly medication containing Brixadi, indicated to treat moderate-to-severe OUD. These efforts aim to expand treatment accessibility and efficacy, propelling advancement significantly.

Naltrexone And Buprenorphine Market Report Highlights:

• North America accounted for the largest revenue share of 39.39% in 2023, driven by robust healthcare infrastructure, high prevalence of substance use disorder, and proactive government initiatives supporting addiction treatment.
• Based on product, the buprenorphine segment dominated the market with a share of 70.02% in 2023 and is anticipated to witness the fastest growth at a CAGR over the forecast period. The segment growth can be attributed to the various strategies adopted by key players such as product launches, collaboration, M&A, regulatory approvals, clinical trials proving efficacy, & other factors that enhance treatment initiation rates.
• Based on route of administration, the oral administration segment held the majority share of 55.87% in 2023. However, in buprenorphine segment, the injectable administration segment held the majority share of 65.04% in 2023.
• Based on application, the OUD segment dominated the market with a share of 69.03% in 2023. Naltrexone is widely recognized for their efficacy in managing OUD, leading to its extensive adoption in treatment programs.
• Based on distribution channel, the hospital pharmacies segment dominated the global market with a share of 48.26% in 2023. Growth can be attributed to their key role in administering parenteral OUD treatments, such as buprenorphine, ensuring physician-supervised care, and facilitating access to essential medications.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Route of Administration
  • 1.2.3. Application
  • 1.2.4. Distribution channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Product and Route of Administration Segment Snapshot
• 2.3. Application and Distribution Channel Segment Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Naltrexone and Buprenorphine Market Variables, Trends, and Scope

• 3.1. Naltrexone and Buprenorphine Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing prevalence of substance use disorders
    • 3.2.1.2. Growing government initiatives to combat the crisis
    • 3.2.1.3. Increasing awareness of opioid use disorder treatment
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Retention and adherence challenges
• 3.3. Naltrexone and Buprenorphine Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTLE Analysis
• 3.4. Pipeline Analysis
• 3.5. Pricing Analysis
• 3.6. Patient and Provider Considerations in Choosing Implantable Treatments
• 3.7. Target Population Analysis
• 3.8. Total Addressable Market (TAM) Analysis for Naltrexone & Buprenorphine Subcutaneous Absorbable Implants

Chapter 4. Naltrexone and Buprenorphine Market Analysis, by Product, 2018 - 2030 (USD Million)

• 4.1. Naltrexone and Buprenorphine: Product Movement Analysis
• 4.2. Naltrexone and Buprenorphine Market Analysis, by Product Market (USD Million)
• 4.3. Naltrexone
  • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Buprenorphine
  • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. BELBUCA
    • 4.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Sublocade
    • 4.4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. Suboxone
    • 4.4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.5. Zubsolv
    • 4.4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Naltrexone and Buprenorphine Market Analysis, by Route of Administration, 2018 - 2030 (USD Million)

• 5.1. Naltrexone and Buprenorphine: Route of Administration Movement Analysis
• 5.2. Naltrexone and Buprenorphine Market Analysis, by Route of Administration Market (USD Million)
• 5.3. Naltrexone
  • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.2. Oral Administration
    • 5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.3. Injectable Administration
    • 5.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.4. Implantable Administration
    • 5.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Buprenorphine
  • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Oral Administration
    • 5.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Injectable Administration
    • 5.4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Implantable Administration
    • 5.4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Naltrexone and Buprenorphine Market Analysis, by Application, 2018 - 2030 (USD Million)

• 6.1. Naltrexone and Buprenorphine: Application Movement Analysis
• 6.2. Naltrexone and Buprenorphine Market Analysis, by Application Market (USD Million)
• 6.3. Naltrexone
  • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. Opioid use disorder (OUD)
    • 6.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2.2. Alcohol use disorder (AUD)
    • 6.3.2.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Buprenorphine
  • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Opioid use disorder (OUD)
    • 6.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Naltrexone and Buprenorphine Market Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

• 7.1. Naltrexone and Buprenorphine: Distribution Channel Movement Analysis
• 7.2. Naltrexone and Buprenorphine Market Analysis, by Distribution Channel Market (USD Million)
• 7.3. Hospital Pharmacies
  • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Retail Pharmacies
  • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Others
  • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Naltrexone and Buprenorphine Market: Regional Estimates and Trend Analysis by Product, by Route of Administration, by Application, by Distribution Channel

• 8.1. Naltrexone and Buprenorphine Market: Regional Outlook
• 8.2. North America
  • 8.2.1. North America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2.3. Competitive/Market Scenario
    • 8.2.2.4. Regulatory Framework
    • 8.2.2.5. Reimbursement scenario
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Canada Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3.3. Competitive/Market Scenario
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. Reimbursement Scenario
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Mexico Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4.3. Competitive/Market Scenario
    • 8.2.4.4. Regulatory Framework
    • 8.2.4.5. Reimbursement Scenario
• 8.3. Europe
  • 8.3.1. Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. UK Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2.3. Competitive/Market Scenario
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. Reimbursement Scenario
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Germany Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3.3. Competitive/Market Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Reimbursement Scenario
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. France Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4.3. Competitive/Market Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Reimbursement Scenario
  • 8.3.5. Spain
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Spain Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5.3. Competitive/Market Scenario
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Reimbursement Scenario
  • 8.3.6. Italy
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Italy Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6.3. Competitive/Market Scenario
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. Reimbursement Scenario
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Denmark Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7.3. Competitive/Market Scenario
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Reimbursement Scenario
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Sweden Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8.3. Competitive/Market Scenario
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Reimbursement Scenario
  • 8.3.9. 6.3.9 Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Norway Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9.3. Competitive/Market Scenario
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Reimbursement Scenario
    • 8.3.9.6. Rest of Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Naltrexone and Buprenorphine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2.3. Competitive/Market Scenario
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. Reimbursement Scenario
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3.3. Competitive/Market Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Reimbursement Scenario
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. India Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4.3. Competitive/Market Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. Reimbursement Scenario
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Australia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5.3. Competitive/Market Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Reimbursement Scenario
  • 8.4.6. Thailand
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Thailand Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6.3. Competitive/Market Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Reimbursement Scenario
  • 8.4.7. South Korea
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. South Korea Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7.3. Competitive/Market Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Reimbursement Scenario
    • 8.4.7.6. Rest of Asia Pacific Naltrexone and Buprenorphine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Brazil Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2.3. Competitive/Market Scenario
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Reimbursement Scenario
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Argentina Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3.3. Competitive/Market Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Reimbursement Scenario
    • 8.5.3.6. Rest of Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. 6.6 MEA
  • 8.6.1. MEA Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. South Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2.3. Competitive/Market Scenario
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. Reimbursement Scenario
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Saudi Arabia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3.3. Competitive/Market Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Reimbursement Scenario
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. UAE Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4.3. Competitive/Market Scenario
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. Reimbursement Scenario
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Kuwait Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5.3. Competitive/Market Scenario
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Reimbursement Scenario
  • 8.6.6. Rest of MEA Naltrexone and Buprenorphine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Key Company Profiles
  • 9.2.1. Indivior PLC
    • 9.2.1.1. Company overview
    • 9.2.1.2. Financial performance
    • 9.2.1.3. Product benchmarking
    • 9.2.1.4. Strategic initiatives
  • 9.2.2. Collegium Pharmaceutical, Inc. (Parent company of BioDelivery Sciences International, Inc.)
    • 9.2.2.1. Company overview
    • 9.2.2.2. Financial performance
    • 9.2.2.3. Product benchmarking
    • 9.2.2.4. Strategic initiatives
  • 9.2.3. Alkermes plc
    • 9.2.3.1. Company overview
    • 9.2.3.2. Financial performance
    • 9.2.3.3. Product benchmarking
    • 9.2.3.4. Strategic initiatives
  • 9.2.4. Orexo AB
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Product benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. Titan Pharmaceuticals, Inc.
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Product benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. Omeros Corporation
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Product benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. F. Hoffmann-La Roche Ltd.
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Product benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Camurus
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Product benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Sun Pharmaceutical Industries Ltd
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Product benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Braeburn, Inc.
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Product benchmarking
    • 9.2.10.4. Strategic initiatives